AW
Andrea Wang-Gillam
Elite in Pancreatic Cancer

Dr. Andrea Wang-Gillam

Division Of Oncology
Creve Coeur, MO
Elite
 in Pancreatic Cancer
Specialties:Oncology
Experience:22 Years
Clinical Trials:Currently Recruiting for 11 Trials
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Andrea Wang-Gillam's experience treating your condition:
About Dr. Andrea Wang-Gillam

Andrea Wang-Gillam is an Oncologist in Creve Coeur, Missouri. Wang-Gillam has been practicing medicine for over 22 years and is rated as an Elite expert by MediFind in the treatment of Pancreatic Cancer. She is also highly rated in 14 other conditions, according to our data. Her top areas of expertise are Pancreatic Cancer, Pancreatic Adenoma, Familial Pancreatic Cancer, Pancreatoblastoma, and Tissue Biopsy. She is licensed to treat patients in Missouri.

Her clinical research consists of co-authoring 83 peer reviewed articles and participating in 42 clinical trials in the past 15 years. In particular, she has co-authored 54 articles and participated in 20 clinical trials in the study of Pancreatic Cancer.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Andrea Wang-Gillam it is best to call her office and ask if your insurance is accepted.

Call to see if your plan is accepted.
Locations
10 Barnes W Dr, Bldg 2 Suite 100, Creve Coeur, MO 63141
Background & Education
Graduate Institution
University Of Arkansas College Of Medicine, 2001
Specialties
Oncology
Licenses
Internal Medicine in MO
Hospital Affiliations
Barnes-Jewish Hospital
Barnes-Jewish West County Hospital
Christian Hospital
Languages Spoken
English
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

42 Clinical Trials
A Phase 1 Study of Pembrolizumab (MK-3475) in Combination With Recombinant Interleukin-12 in Patients With Solid Tumors
Enrollment Status: Recruiting
Publish Date: December 02, 2022
Intervention Type: Procedure, Biological
Study Phase: Phase 1
Phase I Study of Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
Enrollment Status: Recruiting
Publish Date: July 07, 2022
Intervention Type: Procedure, Drug
Study Phase: Phase 1
Non-Operative Management and Early Response Assessment in Rectal Cancer
Enrollment Status: Recruiting
Publish Date: September 09, 2022
Intervention Type: Radiation, Drug, Procedure, Other
Study Phase: Not Applicable
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
Enrollment Status: Recruiting
Publish Date: November 28, 2022
Intervention Type: Biological, Procedure, Drug
Study Drugs: Anetumab ravtansineGemcitabine hydrochlorideIpilimumabNivolumab
Study Phase: Phase 1/Phase 2
A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants With Gastrointestinal Malignancies
Enrollment Status: Recruiting
Publish Date: December 08, 2022
Intervention Type: Drug
Study Drugs: ZimberelimabNab-PaclitaxelGemcitabineAB680 CD73 Inhibitor
Study Phase: Phase 1
MR-guided Pre-operative RT in Gastric Cancer
Enrollment Status: Recruiting
Publish Date: March 16, 2022
Intervention Type: Procedure, Radiation
Study Phase: Not Applicable
Precision Promise Platform Trial for Metastatic Pancreatic Cancer
Enrollment Status: Recruiting
Publish Date: August 22, 2022
Intervention Type: Drug
Study Drugs: GemcitabineNab-paclitaxelSM-88mFOLFIRINOX
Study Phase: Phase 3
Cabozantinib in High Grade Neuroendocrine Neoplasms
Enrollment Status: Recruiting
Publish Date: November 17, 2022
Intervention Type: Procedure, Drug
Study Drug: Cabozantinib
Study Phase: Phase 2
Phase II Study of Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Enrollment Status: Recruiting
Publish Date: November 21, 2022
Intervention Type: Procedure, Device, Drug
Study Drug: Defactinib
Study Phase: Phase 2
A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
Enrollment Status: Recruiting
Publish Date: October 04, 2022
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)
Enrollment Status: Recruiting
Publish Date: November 17, 2022
Intervention Type: Other
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Enrollment Status: Completed
Publish Date: September 23, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients With Advanced Solid Tumors
Enrollment Status: Active, not recruiting
Publish Date: November 21, 2022
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 1
Phase Ib Study of BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Enrollment Status: Terminated
Publish Date: April 21, 2021
Intervention Type: Drug, Procedure
Study Phase: Phase 1
Whipple at the Splenic Artery - A Procedure for Ductal Adenocarcinoma of the Pancreas With Extensive Involvement of the Porto-Mesenteric Axis: A Registry Study
Enrollment Status: Completed
Publish Date: January 22, 2019
Intervention Type: Procedure
A Phase IB Trial of Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
Enrollment Status: Terminated
Publish Date: July 29, 2020
Intervention Type: Drug
Study Phase: Phase 1
Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum (NORMAL-R)
Enrollment Status: Completed
Publish Date: February 18, 2021
Intervention Type: Drug, Radiation
Study Phase: Phase 2
Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders
Enrollment Status: Active, not recruiting
Publish Date: July 28, 2022
Intervention Type: Other
Phase I Study of Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer
Enrollment Status: Completed
Publish Date: July 20, 2021
Intervention Type: Biological, Drug
Study Phase: Phase 1
A Phase I/II Study to Evaluate the Tolerability and Efficacy of BMS-813160 (CCR2/5 Inhibitor) With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Enrollment Status: Active, not recruiting
Publish Date: December 12, 2022
Intervention Type: Drug, Procedure
Study Drugs: BMS-813160NivolumabGemcitabineNab-paclitaxel
Study Phase: Phase 1/Phase 2
A Phase I/II Study of X-82, an Oral Anti-VEGFR Tyrosine Kinase Inhibitor, With Everolimus for Patients With Pancreatic Neuroendocrine Tumors
Enrollment Status: Terminated
Publish Date: July 08, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase I Study Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
Enrollment Status: Completed
Publish Date: January 11, 2018
Intervention Type: Drug
Study Phase: Phase 1
An Open-label, Multi-center Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study and Are Judged by the Investigator to Benefit From Continued Everolimus Treatment
Enrollment Status: Completed
Publish Date: June 11, 2021
Intervention Type: Drug
Study Phase: Phase 4
Phase II Study of FOLFIRINOX Chemotherapy for Treatment of Advanced Gastric, Gastro-esophageal Junction, and Esophageal Tumors
Enrollment Status: Completed
Publish Date: August 25, 2020
Intervention Type: Drug
Study Phase: Phase 2
Prospective Phase I Study of Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer
Enrollment Status: Completed
Publish Date: June 19, 2019
Intervention Type: Drug, Radiation
Study Phase: Phase 1
A Pilot Study of Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy
Enrollment Status: Completed
Publish Date: October 05, 2022
Intervention Type: Procedure, Drug
Study Drugs: 5-FluorouracilLeucovorinLiposomal IrinotecanParicalcitol
Study Phase: Phase 1
Ramucirumab Plus Irinotecan in Patients With Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Enrollment Status: Active, not recruiting
Publish Date: June 23, 2022
Intervention Type: Genetic, Drug
Study Drugs: IrinotecanRamucirumab
Study Phase: Phase 2
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 19, 2022
Intervention Type: Drug, Procedure
Study Drugs: FluorouracilGemcitabine hydrochlorideIrinotecan hydrochlorideOxaliplatinPaclitaxel albumin-stabilized nanoparticle formulation
Study Phase: Phase 2
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Drugs: CPI 613mFolfirinoxFolfirinox
Study Phase: Phase 3
Phase IB Study of FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: September 19, 2016
Intervention Type: Drug, Other
Study Phase: Phase 1
A Phase I Dose-Escalation Trial of Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab Following Cytoreduction in Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
Enrollment Status: Active, not recruiting
Publish Date: November 14, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Pilot Study of PET/MR for Rectal Cancer Treatment Monitoring and Surveillance
Enrollment Status: Terminated
Publish Date: December 08, 2022
Intervention Type: Device
Study Phase: Not Applicable
A Pilot Study Combining Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers
Enrollment Status: Completed
Publish Date: November 24, 2021
Intervention Type: Drug, Radiation, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 1
Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: August 10, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase I/II Study of Indoximod in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Adenocarcinoma of the Pancreas
Enrollment Status: Completed
Publish Date: May 28, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Optimizing Fall-risk Prediction in Older Adults With Cancer
Enrollment Status: Completed
Publish Date: October 14, 2020
Intervention Type: Other
A Randomized Phase 2 Study of Atezolizumab in Combination With Cobimetinib Versus Atezolizumab Monotherapy in Participants With Unresectable Cholangiocarcinoma
Enrollment Status: Active, not recruiting
Publish Date: November 28, 2022
Intervention Type: Procedure, Drug
Study Drugs: AtezolizumabCobimetinib
Study Phase: Phase 2
Project Survival-Prospective Biomarker Discovery to Transform Diagnosis and Treatment for Patients With Pancreatic Diseases and Cancer
Enrollment Status: Unknown status
Publish Date: April 16, 2019
A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab in Combination With Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: May 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
Phase I/II Study Combining Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Enrollment Status: Terminated
Publish Date: August 28, 2019
Intervention Type: Procedure, Drug
Study Phase: Phase 1/Phase 2
A Multicenter Phase I/II Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel With or Without NPC-1C in Patients With Metastatic or Locally Advanced Pancreatic Cancer Previously Treated With FOLFIRINOX
Enrollment Status: Terminated
Publish Date: December 19, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase I Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores in Patients With Treatment-refractory Solid Tumor Malignancies
Enrollment Status: Completed
Publish Date: September 09, 2019
Intervention Type: Biological
Study Phase: Phase 1
View 31 Less Clinical Trials -
83 Total Publications
MR-Guided Radiation Therapy With Concurrent Gemcitabine/Nab-Paclitaxel Chemotherapy in Inoperable Pancreatic Cancer: A TITE-CRM Phase I Trial.
Journal: International journal of radiation oncology, biology, physics
Published: February 18, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
RS
Dr. Rama R. Suresh
Oncology
Elite
Highly rated in
27
conditions
Oncology

BJC HealthCare

Division Of Oncology

10 Barnes W Dr, 
Creve Coeur, MO 
 0.1 mi

Rama Suresh is an Oncologist in Creve Coeur, Missouri. Suresh has been practicing medicine for over 32 years and is rated as a Distinguished expert by MediFind in the treatment of Pancreatic Cancer. She is also highly rated in 27 other conditions, according to our data. Her top areas of expertise are Pancreatic Cancer, Breast Cancer, Colorectal Cancer, Familial Colorectal Cancer, and Tissue Biopsy. She is licensed to treat patients in Missouri. Suresh is currently accepting new patients.

BT
Dr. Benjamin R. Tan
Oncology
Elite
Highly rated in
28
conditions
Oncology

BJC HealthCare

Department Of Radiation Oncology

5225 Mid America Plz, 
Saint Louis, MO 
 14.6 mi

Benjamin Tan is an Oncologist in Saint Louis, Missouri. Tan has been practicing medicine for over 33 years and is rated as an Elite expert by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 28 other conditions, according to our data. His top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Colorectal Cancer, Liver Cancer, Tissue Biopsy, and Endoscopy. He is licensed to treat patients in Missouri. Tan is currently accepting new patients.

KP
Dr. Katrina S. Pedersen
Oncology | Hematology Oncology
Distinguished
Highly rated in
16
conditions
Oncology
Hematology Oncology

BJC HealthCare

Division Of Oncology

10 Barnes W Dr, 
Creve Coeur, MO 

Katrina Pedersen is an Oncologist and a Hematologist Oncology expert in Creve Coeur, Missouri. Pedersen has been practicing medicine for over 14 years and is rated as a Distinguished expert by MediFind in the treatment of Pancreatic Cancer. She is also highly rated in 16 other conditions, according to our data. Her top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Familial Colorectal Cancer, Vertebroplasty, and Bone Graft. She is licensed to treat patients in Missouri. Pedersen is currently accepting new patients.